Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of the...
AstraZeneca's new benralizumab helps severe asthma patients cut back on steroids AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on—or even stop—the unsavory steroid pills they use daily to stave off attacks, a new study showed. Dubbed Zonda, the phase 3 trial found tha...
Find More
Valeant's asset-sale woes continue as Stada, Mundipharma lowball iNova bids Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may not be so easy. The bids rolling in for Valeant’s Australian iNova subsidiary aren’t...
Find More
Sanofi pays €120M to buy into AstraZeneca RSV program Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs...
Find More
[caption id="attachment_1860" align="aligncenter" width="1890"] Chronic Obstructive Pulmonary Disorder[/caption]
Find More
Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease which leads to airflow limitation and interferes with normal breathing. According to World Health Organization, approximately 64 million people are affected by COPD worldwide. World Health Organization estimates Chronic Obstr...
Find More
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology, closely associated with interstitial lung disease that shows similar symptoms but with different mode of action. The disease is known so because it primarily involves the interstitium, where scars develop and progresses towards the ce...
Find More
AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of ...
Find More
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create the largest patient registry for Idiopathic Pulmonary Fibrosis (IPF) The IPF-PRO Registry will be widened to cover 1500 patients spread over 45 clinical sites which will stimulate understand...
Find More
DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. Del...
Find More
Scleroderma is a chronic disease that affects the skin, the connective tissue that supports and hold.....
Find More
Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailori.....
Find More
Axial Spondyloarthritis (axSpA) is an umbrella term for a form of inflammatory form of arthritis ass.....
Find More
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....
Find More
Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....
Find More
Diabetic retinopathy is an eye condition that leads to vision loss and blindness in people who have .....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
